| Catalog | Description | Size | Price (USD) | Qty |
|---|---|---|---|---|
| GBM-2535-50MG | Gabapentin lactam | 50mg | $122.00 | |
| GBM-2535-250MG | Gabapentin lactam | 250mg | $378.00 |
| Bioassays Specification | |
| Bio-Activity | Neuroprotective agent |
| Chemical Name | 4,4-Pentamethylene-2-pyrrolidone |
| Function / Pharmacology | Reduces protein aggregates and improves motor performance in a transgenic mouse model of Huntington’s disease.1 Displays neurotrophic effects, enhancing the formation of dendritic filopodia and inducing a network of F-actin-containing neurites in cultured hippocampal neurons.2 Promotes the survival of cultured central nervous system neurons possibly by opening mitochondrial KATP channels.3 Displays neuroprotective effects in a rat model of acute retinal ischemia.4 |
| CAS# | 64744-50-9 |
| MW | 153.22 |
| Molecular Formula | C9H15NO |
| Solubility | Soluble in DMSO (up to 40 mg/ml) |
| Supplied | powder |
| Storage as supplied | RT |
| Ship temp | Ambient |
| References | 1) Zucker et al. (2004), Gabapentin-lactam, but not gabapentin, reduces protein aggregates and improves motor performance in transgenic mouse model of huntington’s disease; Nauyn Schmiedebergs Arch. Pharmacol., 370 131 2) Henle et al. (2006), Gabapentin-lactam induces dendritic filopodia and motility in cultured hippocampal neurons; J. Pharmacol. Exp. Ther., 319 181 3) Pielen et al. (2004), Retinal ganglion cell survival is enhanced by gabapentin-lactam in vitro: evidence for involvement of mitochondrial KATP channels; Graefes Arch. Clin. Exp. Ophthalmol., 242 240 4) Lagreze et al. (2001), The neuroprotective properties of gabapentin-lactam; Graefes Arch. Clin. Exp. Ophthalmol., 239 845 |
| Antibody Specification | |
| Alternate Names | GBP-L |
| Protein Specification | |
| Purity | >98% |
| Bioassays Specification | |
| Bio-Activity | Neuroprotective agent |
| Chemical Name | 4,4-Pentamethylene-2-pyrrolidone |
| Function / Pharmacology | Reduces protein aggregates and improves motor performance in a transgenic mouse model of Huntington’s disease.1 Displays neurotrophic effects, enhancing the formation of dendritic filopodia and inducing a network of F-actin-containing neurites in cultured hippocampal neurons.2 Promotes the survival of cultured central nervous system neurons possibly by opening mitochondrial KATP channels.3 Displays neuroprotective effects in a rat model of acute retinal ischemia.4 |
| CAS# | 64744-50-9 |
| MW | 153.22 |
| Molecular Formula | C9H15NO |
| Solubility | Soluble in DMSO (up to 40 mg/ml) |
| Supplied | powder |
| Storage as supplied | RT |
| Ship temp | Ambient |
| References | 1) Zucker et al. (2004), Gabapentin-lactam, but not gabapentin, reduces protein aggregates and improves motor performance in transgenic mouse model of huntington’s disease; Nauyn Schmiedebergs Arch. Pharmacol., 370 131 2) Henle et al. (2006), Gabapentin-lactam induces dendritic filopodia and motility in cultured hippocampal neurons; J. Pharmacol. Exp. Ther., 319 181 3) Pielen et al. (2004), Retinal ganglion cell survival is enhanced by gabapentin-lactam in vitro: evidence for involvement of mitochondrial KATP channels; Graefes Arch. Clin. Exp. Ophthalmol., 242 240 4) Lagreze et al. (2001), The neuroprotective properties of gabapentin-lactam; Graefes Arch. Clin. Exp. Ophthalmol., 239 845 |
| Antibody Specification | |
| Alternate Names | GBP-L |
| Protein Specification | |
| Purity | >98% |
